文献速递免疫规划传染病防控与疫情报告

对加拿大猴痘风险人群接种改良安卡拉痘苗-巴伐利亚北欧(MVA-BN)后不良事件的前瞻性监测:加拿大免疫研究网络研究

Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
PubMed 文献 · Vaccine · 2024-01-09

加拿大免疫研究网络在安大略省多伦多和不列颠哥伦比亚省温哥华对接种MVA-BN的猴痘风险人群进行前瞻性安全性监测,接种者在每剂后7天和30天填写调查问卷,并与未接种对照1:1匹配。结果显示接种组需医疗评估或影响工作/学校的事件少于对照组(3.3% vs 7.1%,p<0.010),无住院、无严重神经疾病、皮肤病或心肌炎病例。

要点

  • 60%的接种者报告轻至中度注射部位疼痛,接种组需医疗评估或影响工作/学校的事件少于对照组(3.3% vs 7.1%,p<0.010)。
  • 接种者中8.4%为HIV阳性,HIV阳性者局部注射部位反应少于HIV阴性者(48% vs 61%,p=0.021),但需医疗评估或影响工作/学校的事件更多(7.1% vs 3.1%,p=0.040)。
  • 接种后7天或30天内无住院,未发现严重神经疾病、皮肤病或心肌炎病例。

核心结论

  • MVA-BN疫苗用于猴痘预防时似乎安全,严重不良事件频率低,未观察到住院。

研究设计与样本

  • 加拿大国家疫苗安全网络(CANVAS)在安大略省多伦多和不列颠哥伦比亚省温哥华公共卫生疫苗接种活动中开展前瞻性安全性监测。
  • 接种者在每剂MVA-BN后7天和30天收到调查问卷,报告不良健康事件;未接种对照来自同期评估COVID-19疫苗安全性的疫苗安全项目。
  • 接种组与未接种对照按年龄组、性别、生理性别和省级研究站点1:1匹配;共1,173名接种者完成7天调查,其中75%(n=878)完成30天调查。

主要发现

  • 60%的接种者报告轻至中度注射部位疼痛。
  • 接种者中8.4%为HIV阳性;与HIV阴性接种者相比,HIV阳性者局部注射部位反应更少(48% vs 61%,p=0.021),但需医疗评估或影响工作/学校的事件更多(7.1% vs 3.1%,p=0.040)。
  • 接种组需医疗评估或影响工作/学校的事件少于对照组(3.3% vs 7.1%,p<0.010)。
  • 接种后7天或30天内无参与者住院;未发现严重神经疾病、皮肤病或心肌炎病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MVA-BN is an orthopoxvirus vaccine that provides protection against both smallpox and mpox. In June 2022, Canada launched a publicly-funded vaccination campaign to offer MVA-BN to at-risk populations including men who have sex with men (MSM) and sex workers. The safety of MVA-BN has not been assessed in this context. To address this, the Canadian National Vaccine Safety Network (CANVAS) conducted prospective safety surveillance during public health vaccination campaigns in Toronto, Ontario and in Vancouver, British Columbia. Vaccinated participants received a survey 7 and 30 days after each MVA-BN dose to elicit adverse health events. Unvaccinated individuals from a concurrent vaccine safety project evaluating COVID-19 vaccine safety were used as controls. Vaccinated and unvaccinated participants that reported a medically attended visit on their 7-day survey were interviewed. Vaccinated participants and unvaccinated controls were matched 1:1 based on age group, gender, sex and provincial study site. Overall, 1,173 vaccinated participants completed a 7-day survey, of whom 75 % (n = 878) also completed a 30-day survey. Mild to moderate injection site pain was reported by 60 % of vaccinated participants. Among vaccinated participants 8.4 % were HIV positive and when compared to HIV negative vaccinated individuals, local injection sites were less frequent in those with HIV (48 % vs 61 %, p = 0.021), but health events preventing work/school or requiring medical assessment were more frequent (7.1 % vs 3.1 %, p = 0.040). Health events interfering with work/school, or requiring medical assessment were less common in the vaccinated group than controls (3.3 % vs. 7.1 %, p < 0.010). No participants were hospitalized within 7 or 30 days of vaccination. No cases of severe neurological disease, skin disease, or myocarditis were identified. Our results demonstrate that the MVA-BN vaccine appears safe when used for mpox prevention, with a low frequency of severe adverse events and no hospitalizations observed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Muller MP, Navarro C, Wilson SE, et al. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study. Vaccine. 2024. PMID: 38199921. doi:10.1016/j.vaccine.2023.12.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。